Triazolam intranasal - Fabre Kramer
Alternative Names: Hypnostat; TGAR01HLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Questcor Pharmaceuticals
- Developer Fabre-Kramer Pharmaceuticals
- Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 14 Aug 2014 Questcor Pharmaceuticals has been acquired by Mallinckrodt plc
- 21 Jan 2009 Phase-II clinical trials in Insomnia in USA (Intranasal)
- 13 Oct 2005 Discontinued - Phase-II for Insomnia in USA (Intranasal)